Compare · ASPE vs JNJ
ASPE vs JNJ
Side-by-side comparison of Aspen Neuroscience Inc. (ASPE) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ASPE and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $664.95B, about 1838.2x ASPE ($361.7M).
- Over the past year, ASPE is down 6.9% and JNJ is up 48.1% - JNJ leads by 55.0 points.
- JNJ has been more active in the news (20 items in the past 4 weeks vs 10 for ASPE).
- JNJ has more recent analyst coverage (25 ratings vs 0 for ASPE).
- Company
- Aspen Neuroscience Inc.
- Johnson & Johnson
- Price
- -
- -
- Market cap
- $361.7M
- $664.95B
- 1M return
- -6.89%
- +7.74%
- 1Y return
- -6.89%
- +48.12%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- News (4w)
- 10
- 20
- Recent ratings
- 0
- 25
Aspen Neuroscience Inc.
Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company focused on developing autologous induced-pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases with high unmet medical need.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest ASPE
- SEC Form SCHEDULE 13D filed by Aspen Neuroscience Inc.
- SEC Form SCHEDULE 13G filed by Aspen Neuroscience Inc.
- SEC Form SCHEDULE 13G filed by Aspen Neuroscience Inc.
- Director Thompson Peter A. converted options into 2,589,132 shares and bought $15,000,000 worth of shares (1,000,000 units at $15.00) (SEC Form 4)
- Director Orbimed Advisors Llc converted options into 2,589,132 shares and bought $15,000,000 worth of shares (1,000,000 units at $15.00) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Aspen Neuroscience Inc.
- Large owner Arch Venture Fund X, L.P. bought $19,999,995 worth of shares (1,333,333 units at $15.00) and converted options into 2,421,589 shares (SEC Form 4)
- Large owner Arch Venture Partners Xiv, L.P. bought $18,000,000 worth of shares (1,200,000 units at $15.00) (SEC Form 4)
- Director Spaventa Andrew converted options into 250,415 shares (SEC Form 4)
- Executive Chair Hasnain Faheem converted options into 36,349 shares (SEC Form 4)
Latest JNJ
- Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide
- Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients
- FDA Approval for RYBREVANT FASPRO issued to JANSSEN BIOTECH
- Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer
- Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results
- Johnson & Johnson to Host Enterprise Business Review
- SEC Form 13F-HR filed by Johnson & Johnson
- RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
- Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule
- Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer